SCHEMBL5202041

SCHEMBL5202041

CC1=C(C(=O)O)C(c2ccco2)C2=C(CCCC2=O)N1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 9/20 0.76
ALDH1A1 P00352 7/20 0.54
KDM4E B2RXH2 6/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
MAPT P10636 3/20 0.54
GAA P10253 3/20 0.54
HPGD P15428 3/20 0.54
MEN1 O00255 2/20 0.54
PKM P14618 2/20 0.54
ALOX12 P18054 2/20 0.54
HTT P42858 2/20 0.54
KMT2A Q03164 2/20 0.54
HIF1A Q16665 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
LMNA P02545 3/20 0.53
NPSR1 Q6W5P4 2/20 0.52
TP53 P04637 2/20 0.52
TSHR P16473 3/20 0.52
HSD17B10 Q99714 2/20 0.52
GLA P06280 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2990862 0.86 KDM4E (0.66) FFAR3ALDH1A1KDM4ESMN1; SMN2GAA
SCHEMBL5064643 0.82 FFAR3 (1.00) FFAR3KDM4E
SCHEMBL5197527 0.81 FFAR3 (0.60) FFAR3ALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL5476494 0.80 FFAR3 (0.54) FFAR3ALDH1A1KDM4EGAAHPGD
SCHEMBL5065030 0.79 FFAR3 (0.68) FFAR3ALDH1A1KDM4ESMN1; SMN2GAA
SCHEMBL30834749 0.79 FFAR3 (1.00) FFAR3KDM4E
SCHEMBL27372710 0.78 KDM4E (0.77) FFAR3ALDH1A1KDM4EMAPTMEN1
SCHEMBL5222960 0.77 HSD17B10 (0.49) FFAR3ALDH1A1KDM4ESMN1; SMN2GAA
SCHEMBL5201411 0.77 ALDH1A1 (0.58) FFAR3ALDH1A1KDM4ESMN1; SMN2MAPT
SCHEMBL4256216 0.76 ALDH1A1 (0.50) FFAR3ALDH1A1KDM4ESMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1812080-A2 GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS Arena Pharmaceuticals, Inc. (US) 2007-08-01 EP claimed
WO-2006052566-A2 GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2006-05-18 WO claimed
EP-1812080-A2 GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS Arena Pharmaceuticals, Inc. (US) 2007-08-01 EP disclosed
WO-2006052566-A2 GPR41 AND MODULATORS THEREOF FOR THE TREATMENT OF INSULIN-RELATED DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2006-05-18 WO disclosed